Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 01, 2015 8:22 AM ET


Company Overview of NantWorks, LLC

Company Overview

NantWorks, LLC develops an application for image recognition. The company uses semiconductor chips, switches and encryption technologies, augmented reality, novel object and voice recognition technologies, broadband telecommunications services, and ultra-low power remote monitoring technologies. NantWorks, LLC was incorporated in 2007 and is based in Culver City, California.

9920 Jefferson Boulevard

Culver City, CA 90232

United States

Founded in 2007





Key Executives for NantWorks, LLC

Founder, Chief Executive Officer, and Chairman
Age: 62
Compensation as of Fiscal Year 2015.

NantWorks, LLC Key Developments

NantWorks, LLC Presents at Milken Institute, Global Conference 2015, Apr-27-2015 10:45 AM

NantWorks, LLC Presents at Milken Institute, Global Conference 2015, Apr-27-2015 10:45 AM. Venue: 2025 Ave Of The Stars, Los Angeles, CA 90067, California, United States. Speakers: Patrick Soon-Shiong, Founder, Chief Executive Officer, and Chairman.

Sorrento Therapeutics, Inc. and NantWorks to Establish Global Strategic Collaboration to Jointly Develop Next Generation Immunotherapies

Sorrento Therapeutics (SRNE) announced that it has entered into a binding agreement with NantWorks. Under the terms of the agreement, NantWorks and SRNE will establish a global strategic collaboration to jointly develop next generation immunotherapies for the treatment of cancer and auto-immune diseases. NantWorks, through a subsidiary, and SRNT intend to establish the first joint venture - The Immunotherapy Antibody JV - as an independent biotechnology company with $20 million initial joint funding. The Immunotherapy Antibody JV will focus on accelerating the development of multiple immuno-oncology monoclonal antibodies (mAbs) for the treatment of cancer, including but not limited to anti-PD-1, anti-PD-L1, anti-CTLA4 mAbs, and other immune-check point antibodies as well as antibody drug conjugates (ADCs) and bispecific antibodies.

Similar Private Companies By Industry

Company Name Region
ADAPT Corporation United States
Infoscore, Inc. United States
MVRS, Inc. United States
Vadium Technology, Inc. United States
DynEd International, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NantWorks, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at